Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data
Abstract Background Bisphosphonates are the mainstay drugs for osteoporosis, but in clinical practice, they are often ineffective due to low compliance. However, there have been few studies examining compliance on a product-by-product basis or in detail in Japan. This study aimed to clarify the bisp...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | Journal of Pharmaceutical Health Care and Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40780-025-00434-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850183838161960960 |
|---|---|
| author | Kenji Kabeya Hiroki Satoh Natsuyo Yanagi Yasufumi Sawada |
| author_facet | Kenji Kabeya Hiroki Satoh Natsuyo Yanagi Yasufumi Sawada |
| author_sort | Kenji Kabeya |
| collection | DOAJ |
| description | Abstract Background Bisphosphonates are the mainstay drugs for osteoporosis, but in clinical practice, they are often ineffective due to low compliance. However, there have been few studies examining compliance on a product-by-product basis or in detail in Japan. This study aimed to clarify the bisphosphonate compliance from the viewpoints of product selection, formulation, and patient characteristics using medical insurance claim data in Japan, to generate useful knowledge for improving bisphosphonate compliance. Methods Bisphosphonate records for osteoporosis treatment were extracted from Japanese medical insurance claim data (2021–2023), and the Medication Possession Ratio (MPR) of each patient was calculated from the records. The calculated MPR and compliance classification (Compliant/Non-compliant/Dropout) based on dispensing status were statistically analyzed from viewpoints of drug product, dose form/frequency, and patient sex/age to investigate the influence of each factor on compliance. Results The mean MPR for all patients (N = 63,197) was 76.7%. Product choice influenced compliance, with significance in 230 pairs among the 71 major products. Tablet was the most compliant formulation, and compliance was better with longer dose intervals. Women showed significantly better compliance and older age was associated with better compliance. Conclusions This study generated new data regarding product-specific MPRs, and clarified that product selection influences patient compliance. The study also supported previous findings that sex, age, and dose frequency influence compliance. It is expected that the findings of this study will be utilized for drug development, drug selection and patient guidance in clinical practice, to improve the treatment environment for osteoporosis. |
| format | Article |
| id | doaj-art-416302910b7b4eabb93de60c3a17d995 |
| institution | OA Journals |
| issn | 2055-0294 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Pharmaceutical Health Care and Sciences |
| spelling | doaj-art-416302910b7b4eabb93de60c3a17d9952025-08-20T02:17:13ZengBMCJournal of Pharmaceutical Health Care and Sciences2055-02942025-04-011111710.1186/s40780-025-00434-5Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim dataKenji Kabeya0Hiroki Satoh1Natsuyo Yanagi2Yasufumi Sawada3Laboratory of Drug Lifetime Management, Graduate School of Pharmaceutical Sciences, The University of TokyoLaboratory of Drug Lifetime Management, Graduate School of Pharmaceutical Sciences, The University of TokyoLaboratory of Drug Lifetime Management, Graduate School of Pharmaceutical Sciences, The University of TokyoLaboratory of Drug Lifetime Management, Graduate School of Pharmaceutical Sciences, The University of TokyoAbstract Background Bisphosphonates are the mainstay drugs for osteoporosis, but in clinical practice, they are often ineffective due to low compliance. However, there have been few studies examining compliance on a product-by-product basis or in detail in Japan. This study aimed to clarify the bisphosphonate compliance from the viewpoints of product selection, formulation, and patient characteristics using medical insurance claim data in Japan, to generate useful knowledge for improving bisphosphonate compliance. Methods Bisphosphonate records for osteoporosis treatment were extracted from Japanese medical insurance claim data (2021–2023), and the Medication Possession Ratio (MPR) of each patient was calculated from the records. The calculated MPR and compliance classification (Compliant/Non-compliant/Dropout) based on dispensing status were statistically analyzed from viewpoints of drug product, dose form/frequency, and patient sex/age to investigate the influence of each factor on compliance. Results The mean MPR for all patients (N = 63,197) was 76.7%. Product choice influenced compliance, with significance in 230 pairs among the 71 major products. Tablet was the most compliant formulation, and compliance was better with longer dose intervals. Women showed significantly better compliance and older age was associated with better compliance. Conclusions This study generated new data regarding product-specific MPRs, and clarified that product selection influences patient compliance. The study also supported previous findings that sex, age, and dose frequency influence compliance. It is expected that the findings of this study will be utilized for drug development, drug selection and patient guidance in clinical practice, to improve the treatment environment for osteoporosis.https://doi.org/10.1186/s40780-025-00434-5BisphosphonateComplianceMPR (medication possession ratio)Claim data |
| spellingShingle | Kenji Kabeya Hiroki Satoh Natsuyo Yanagi Yasufumi Sawada Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data Journal of Pharmaceutical Health Care and Sciences Bisphosphonate Compliance MPR (medication possession ratio) Claim data |
| title | Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data |
| title_full | Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data |
| title_fullStr | Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data |
| title_full_unstemmed | Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data |
| title_short | Bisphosphonate compliance in Japan from the perspective of product, formulation, and patient characteristics: analysis of medical insurance claim data |
| title_sort | bisphosphonate compliance in japan from the perspective of product formulation and patient characteristics analysis of medical insurance claim data |
| topic | Bisphosphonate Compliance MPR (medication possession ratio) Claim data |
| url | https://doi.org/10.1186/s40780-025-00434-5 |
| work_keys_str_mv | AT kenjikabeya bisphosphonatecomplianceinjapanfromtheperspectiveofproductformulationandpatientcharacteristicsanalysisofmedicalinsuranceclaimdata AT hirokisatoh bisphosphonatecomplianceinjapanfromtheperspectiveofproductformulationandpatientcharacteristicsanalysisofmedicalinsuranceclaimdata AT natsuyoyanagi bisphosphonatecomplianceinjapanfromtheperspectiveofproductformulationandpatientcharacteristicsanalysisofmedicalinsuranceclaimdata AT yasufumisawada bisphosphonatecomplianceinjapanfromtheperspectiveofproductformulationandpatientcharacteristicsanalysisofmedicalinsuranceclaimdata |